#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myxofibrosarcoma Idiopathic pulmonary fibrosis Vascular malformation Small intestine adenocarcinoma Pleural mesothelioma malignant Transitional cell cancer of the renal pelvis and ureter Arrhythmogenic right ventricular dysplasia Thalassaemia beta Fibrosarcoma metastatic Glycogen storage disease type V Autoimmune hepatitis Eosinophilic oesophagitis Hereditary neuropathic amyloidosis Hepatobiliary cancer Infantile spasms More trials…

    Learn about Rare Diseases

    Immunodeficiency congenital – Life with Disease Leiomyosarcoma recurrent – Diagnostics Hepatic angiosarcoma – Life with Disease Arterial tortuosity syndrome – Treatment Leiomyosarcoma metastatic – Trials in Disease Mucopolysaccharidosis II Alport’s syndrome – Basic Information Shprintzen-Goldberg syndrome – Basic Information Hepatoblastoma – Trials in Disease Medulloblastoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Satralizumab Vinorelbine Tartrate Gsk3915393 AP31969 SULFATE Protein C GRNA1599 Fludeoxyglucose (18F) Mdna11 ZOLPIDEM TARTRATE Hydralazine Hydrochloride Mavorixafor Ofloxacin Hydrochloride Clemastine Fumarate ABBV-8736 Alectinib Hydrochloride Pimozide Valbenazine Ditosylate Somatostatin Apixaban Lasn01 More therapies…

    Learn about Your Condition

    Pleural mesothelioma malignant Nasopharyngeal cancer Rectal cancer stage III Meniscus operation Mitral valve disease Aneurysm ruptured Metabolic disorder Erythema multiforme Diffuse large B-cell lymphoma Short stature Diabetic foot Intracranial aneurysm Large cell lung cancer stage 0 Choroidal neovascularisation Endometrial cancer stage I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Clinical Medical Center Osijek

Clinical Medical Center Osijek

Ulica Josipa Huttlera 4, Osijek, 31000, Croatia

Want to learn more about this study or check if you can participate? Contact us.

  • Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Not recruiting

    3 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Leuprorelin Acetate
    • Anastrozole
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Metformin Embonate
    Bulgaria Croatia Germany Greece Hungary Poland +3

  • Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

    Not recruiting

    3 1 1
    Belgium Croatia France Germany Greece Hungary +4

  • Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Diabetic retinal oedema
    Investigated Drugs:
    • Eye103
    • Fluorescein Sodium
    • Ranibizumab
    Austria Croatia Czechia France Germany Hungary +6

  • Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Eftilagimod Alfa
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia Germany Greece +9

  • Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    Investigated Drugs:
    • Cabozantinib
    Croatia Hungary Poland Romania

  • Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Nivolumab
    Croatia Czechia Estonia France Germany Hungary +6

  • Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis relapse
    Investigated Drugs:
    • A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)
    • A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 Cvr-167)
    • B/Austria/1359417/2021-Like Strain (B/Singapore/Wuh4618/2021)
    Austria Belgium Bulgaria Croatia Czechia Denmark +15
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!